ARTICLE | Clinical News

No genotoxicity in alagebrium studies

May 5, 2005 12:40 AM UTC

Alteon (ALT) said interim results from preclinical toxicity studies of alagebrium show that liver alterations previously seen in rats, which led to the suspension of enrollment in three trials, are not caused by genotoxicity pathways, but may be a result of the male rat metabolism. The studies are expected to be completed mid-year. ...